Arbutus Biopharma (ABUS) CEO awarded 28,000 RSUs and 71,700 options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Arbutus Biopharma Corp
The RSUs vest in three equal annual installments beginning one year from the grant date, contingent on continued service, and shares will be automatically sold at vesting to cover tax withholding. She also received a stock option for 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date.
This option vests over four years, with 1/48th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to her continued service. After these grants, she directly holds 28,000 common shares and options for 71,700 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Androski Lindsay
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 71,700 | $0.00 | -- |
| Grant/Award | Common Shares | 28,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 71,700 shares (Direct);
Common Shares — 28,000 shares (Direct)
Footnotes (1)
- Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
FAQ
What insider transaction did ABUS President and CEO Lindsay Androski report?
Lindsay Androski reported receiving equity awards from Arbutus Biopharma. She was granted 28,000 restricted stock units and a stock option for 71,700 common shares on 02/02/2026, both subject to multi-year vesting tied to her continued service with the company.
How many Arbutus Biopharma (ABUS) RSUs were granted to the CEO?
The CEO received 28,000 restricted stock units. Each RSU represents a contingent right to receive one common share, vesting in three equal annual installments starting one year after the grant date, provided she continues to serve the company on each vesting date.
What stock options did the Arbutus Biopharma (ABUS) CEO receive?
She received a stock option to buy 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date. The option vests over four years in substantially equal monthly installments, starting one month after the grant date.
What are the vesting terms for the ABUS CEO’s RSU grant?
The 28,000 RSUs vest in three equal annual installments beginning one year from the grant date. Vesting requires the CEO’s continuous service at each vesting date, and at each vesting, shares will automatically be sold to satisfy tax withholding obligations.
How do the ABUS CEO’s stock options vest over time?
The 71,700-share stock option vests over four years. One forty-eighth of the shares vest in substantially equal monthly installments starting one month after the grant date, subject to the CEO remaining in continuous service through each monthly vesting date.